Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials

Brainstorm Cell Therapeutics ( (BCLI) ) has issued an announcement.

Brainstorm Cell Therapeutics, Inc. has released a presentation highlighting its autologous cell therapy platform, NurOwn®, for neurological disorders such as ALS and MS. The company is progressing towards a Phase 3b trial, with finalized clinical site agreements and manufacturing capabilities in place. NurOwn® has shown promise in prior trials, demonstrating improvements in patients and robust biomarker data supporting its mechanism of action. The presentation also outlines the company’s experienced team and strategic milestones, including first patient enrollment expected by December 2024.

See more insights into BCLI stock on TipRanks’ Stock Analysis page.